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Long-lasting, latently infected resting CD4+ T cells are the greatest obstacle to 
obtaining a cure for HIV infection, as these cells can persist despite decades of 
treatment with antiretroviral therapy (ART). Estimates indicate that more than 
70 years of continuous, fully suppressive ART are needed to eliminate the HIV 
reservoir1. Alternatively, induction of HIV from its latent state could accelerate the 
decrease in the reservoir, thus reducing the time to eradication. Previous attempts to 
reactivate latent HIV in preclinical animal models and in clinical trials have measured 
HIV induction in the peripheral blood with minimal focus on tissue reservoirs and 
have had limited effect2–9. Here we show that activation of the non-canonical NF-κB 
signalling pathway by AZD5582 results in the induction of HIV and SIV RNA expression 
in the blood and tissues of ART-suppressed bone-marrow–liver–thymus (BLT) 
humanized mice and rhesus macaques infected with HIV and SIV, respectively. 
Analysis of resting CD4+ T cells from tissues after AZD5582 treatment revealed 
increased SIV RNA expression in the lymph nodes of macaques and robust induction 
of HIV in almost all tissues analysed in humanized mice, including the lymph nodes, 
thymus, bone marrow, liver and lung. This promising approach to latency reversal—in 
combination with appropriate tools for systemic clearance of persistent HIV 
infection—greatly increases opportunities for HIV eradication.
Latently infected cells carrying an integrated replication-competent 
provirus that contribute to viral rebound after the interruption of 
ART (termed the HIV reservoir) are not detected and eliminated by 
the immune system or current therapeutics. Therefore, the HIV res-
ervoir has been targeted by approaches to reverse latency and induce 
viral antigen production (that is, ‘HIV reactivation’)2–9, which renders 
infected cells susceptible to virus-induced cell death or clearance by 
the immune system. Previous approaches to HIV reactivation have 
been modestly effective and have not demonstrated reactivation of 
HIV in resting CD4+ T cells in tissues2–9.
HIV induction in vitro by SMAC mimetics
The lack of specificity of molecules that activate the NF-κB pathway 
as latency-reversal agents (LRAs) often leads to toxicities that pre-
vent clinical implementation10. We tested the induction of HIV and 
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SIV transcription in latently infected cells by the non-canonical (nc)
NF-κB pathway. This pathway activates a limited number of cellular 
genes and a more-gradual but persistent activation of NF-κB-driven 
transcription than the canonical (c)NF-κB pathway11. Mimetics of the 
second mitochondrial-derived activator of caspases (SMAC) activate 
the ncNF-κB pathway by inhibiting the cellular inhibitor of apoptosis 
protein 1 (cIAP1) and cIAP2. cIAP1 continually represses the ncNF-κB 
pathway by constitutively degrading the NF-κB-inducing kinase, thus 
preventing processing of p100 into p5212; this repression can be relieved 
in CD4+ T cells by in vitro treatment with the SMAC mimetic AZD5582 
(Fig. 1a and Extended Data Fig. 1). Compared with other SMAC mimet-
ics, AZD5582 had a superior capacity to reverse HIV latency in vitro13 
(Fig. 1b). AZD5582 also induced replication-competent HIV expres-
sion in resting CD4+ T cells from ART-suppressed HIV-infected donors 
(Fig. 1c). AZD5582 induced five- to tenfold fewer genes than the protein 
kinase C agonist ingenol B (Fig. 1d), a cNF-κB pathway inducer and 
activator of several transcription factors. By specifically targeting the 
ncNF-κB signalling pathway, AZD5582 has limited pleotropic effects, 
which may translate to fewer off-target effects14.
Latency reversal in BLT humanized mice
BLT mice were infected with HIV-1JR-CSF (Supplementary Table 1) and sup-
pressed with ART15–18 (Fig. 2a, b). Mice then received a single intraperi-
toneal injection of 3 mg kg−1 AZD5582 or vehicle. No changes in plasma 
HIV RNA levels were detected in vehicle-control-treated mice at 24 or 
48 h nor in AZD5582-treated mice 24 h after AZD5582 administration 
(Fig. 2c). However, 48 h after AZD5582 treatment increased HIV RNA 
expression was detected in the plasma of 3 out of 6 (50%) and 3 out 
of 4 (75%) mice in two independent experiments (Fig. 2c). These data 
demonstrate that a single dose of AZD5582 can induce HIV production, 
resulting in significant viraemia (up to 1,574 HIV RNA copies per ml 
plasma) in ART-treated BLT mice (Supplementary Table 2).
The hallmark of HIV persistence in humans is the presence of inducible 
HIV in resting CD4+ T cells. Therefore, resting cells from primary (bone 
marrow and thymic organoid), secondary (lymph node and spleen) and 
effector (liver and lung) immune tissues were isolated from HIV-infected 
ART-suppressed BLT mice 48 h after treatment with vehicle control or 
AZD558217,19,20. The levels of HIV RNA in resting CD4+ T cells from AZD5582-
treated mice were 11-fold (bone marrow, P = 0.0201), 21-fold (thymic 
organoid, P = 0.0038), 12-fold (lymph node, P = 0.0004), 1.4-fold (spleen, 
P = 0.0426), 24-fold (liver, P = 0.0145) and 3.2-fold (lung, P = 0.0029) higher 
than controls (Fig. 2d). These results were confirmed in a second inde-
pendent experiment (Extended Data Fig. 2). No notable differences in 
cell-associated HIV DNA were noted between mice treated with vehicle 
control or AZD5582 (Supplementary Table 3). These results demonstrate 
that AZD5582 induces systemic HIV RNA production in resting CD4+ 
T cells, indicative of latency reversal in this important cellular source of 
persistent HIV infection. We also isolated cells from the peripheral blood, 
female reproductive tract and brain of HIV-infected ART-suppressed BLT 
mice 48 h after treatment with AZD5582 or vehicle control. As too few 
CD4+ T cells were available for cell sorting from these compartments, 
RNA was extracted from total cells and analysed for the presence of HIV 
RNA in each tissue. The levels of HIV RNA were significantly higher in 
the female reproductive tract (3.4-fold, P = 0.0152) and brain (8.7-fold, 
P = 0.0147) of AZD5582-treated mice compared with vehicle controls, but 
not in the blood (P = 0.3095) (Fig. 2e). Together, these results show that 
AZD5582 treatment induces systemic HIV RNA production in BLT mice.
Pharmacodynamics and safety in BLT mice
Target engagement after treatment with AZD5582 was confirmed ex 
vivo by the degradation of cIAP1 (proximal) and p100 (distal), targets 
of SMAC in the ncNF-κB pathway (Extended Data Fig. 3a). In vivo tar-
get engagement was demonstrated in resting CD4+ T cells isolated 
from thymus, spleen, lymph nodes, liver, lung and bone marrow of 
BLT mice treated with a single dose of 3 mg kg−1 AZD5582 or vehicle 
control (Extended Data Fig. 3b). These results were confirmed by 
immunohistochemical analysis of the thymic organoid of HIV-infected 
ART-suppressed BLT mice. This analysis showed a marked reduction 
in cIAP1 expression in the thymic organoid of AZD5582-treated mice 
(Extended Data Fig. 3c).
To study off-target or immune-mediated toxicities of AZD5582, we 
measured serum chemistry, T cell activation and a panel of plasma 
cytokines after in vivo treatment of immunocompetent BALB/c mice. 
AZD5582 administration resulted in mild and transient increases in alanine 
aminotransferase and aspartate aminotransferase that resolved a few days 
after treatment. No other changes in serum chemistries were noted (Sup-
plementary Table 4). In addition, no differences were noted in the levels of 
activated (CD38+HLA-DR+) CD4+ or CD8+ T cells in BLT mice treated with 
AZD5582 or vehicle control (Supplementary Table 5) or in plasma levels of 
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Fig. 1 | Efficient in vitro AZD5582 target engagement and induction of HIV 
transcription. a, Total CD4+ T cells were treated with a broad range of 
concentrations (10 pM–1 μM) of AZD5582 overnight, and cell lysates were 
analysed by immunoblot, probing for cIAP1 and p100/p52 as indicated (top; 
representative of 10 experiments). Immunoblot analysis of isolated total CD4+ 
T cell lysates after treatment with 100 nM AZD5582, examining components of 
the cNF-κB and ncNF-κB pathways over a 48-h time course after treatment 
(middle and bottom; representative of three and four experiments, 
respectively). b, DMSO-normalized reporter signal induced by a dose titration 
of a panel of mono- and bivalent SMAC mimetics in a Jurkat luciferase reporter 
model of HIV-1 latency with 48 h exposure. Symbols represent technical 
replicates from a single run and are representative of three independent 
experiments. Lines represent a four-parameter logistic-regression model fit.  
c, Infectious units per million resting CD4+ T cells induced by DMSO or 100 nM 
AZD5582 were determined in a limiting dilution quantitative viral outgrowth 
assay. PHA, phytohaemagglutinin. d, Volcano plots summarizing mean up- and 
downregulated genes at 2, 6 and 24 h after treatment with ingenol B or 
AZD5582 compared with treatment with DMSO alone. The mean log2-
transformed fold change is shown on the x axis and log10-adjusted P values 
(two-sided Wald test) are shown on the y axis. Dashed lines represent 
thresholds of log2-transformed fold change of 1 and adjusted P < 0.05. The data 
shown represent the mean fold change across four donors and one experiment. 
For gel source data, see Supplementary Fig. 1.
infection (Fig. 3a and Supplementary Table 7)22,23. Suppression of SIV 
viraemia below 60 copies per ml (standard assay limit of detection) 
was achieved in all macaques in 2–20 weeks and ART was continued for 
55–67 weeks before further treatment (Fig. 3b). On the basis of phar-
macokinetic and pharmacodynamic data from uninfected macaques 
(Extended Data Fig. 4a) as well as protocols for SMAC mimetics used in 
oncology, intravenous infusions of 0.1 mg kg−1 AZD5582 were admin-
istered weekly to 12 SIV-infected ART-suppressed rhesus macaques 
for 3 or 10 weeks (Fig. 3a). Nine SIV-infected ART-suppressed rhesus 
macaques served as controls (Fig. 3a). Plasma concentrations of 
AZD5582 measured after the first, third, sixth and tenth dose showed 
that drug exposures in SIV-infected ART-suppressed macaques were 
consistent across the treatment period and comparable to those 
observed in uninfected rhesus macaques (Extended Data Fig. 4b).
Latency reversal, defined as on-ART viraemia increasing from less 
than 60 copies per ml of plasma to more than 60 copies per ml of 
plasma after AZD5582 treatment, was observed as early as 96 h after 
the first dose and reached levels as high as 1,390 copies per ml in SIV-
infected rhesus macaques (Fig. 3c, d). On-ART viraemia >60 copies per 
ml of plasma was observed in 5 out of 12 rhesus macaques (42%), cor-
responding to 5 out of 9 rhesus macaques (55%) that received 10 doses 
of AZD5582 (Fig. 3c, d). Multiple instances of sustained viraemia >60 
copies per ml between AZD5582 doses were observed. Out of 140 viral 
load measurements performed on the 5 macaques that exhibited on-
ART viraemia during AZD5582 treatment, 64 were >60 copies per ml 
(46%); in the macaque with the greatest frequency of reactivation, this 
proportion was 15 out of 28 (53%). Longitudinal examination of plasma 
virus by single-genome sequencing analysis of the SIVmac239 env gene 
in all rhesus macaques that experienced AZD5582-induced on-ART 
viraemia was performed at four selected time points: 2 weeks after 
infection (near peak viraemia), 8 weeks after infection (immediately 
before ART initiation), and at 2 time points separated by 26–42 days 
during AZD5582 treatment. Phylogenetic analyses showed several 
patterns of virus reactivation (Extended Data Fig. 5). In two rhesus 
macaques (RDl16 and RKn16), most of the reactivated virus sequences 
were phylogenetically closer to sequences at eight weeks after infection 
rather than peak viraemia and were unique, indicating that the variants 
produced during AZD5582 treatment originated from multiple cells 
that were seeded at the time of ART initiation24. In two other rhesus 
macaques (RKl16 and RDm16), a large fraction of the viruses produced 
during AZD5582 treatment showed identical sequences, suggesting 
that latency reversal occurred from a single cell or a clonally expanded 
population of infected cells. These clones clustered with both peak 
and pre-ART time points and were accompanied by additional unique 
sequences. In one rhesus macaque (RLy15), a single virus sequence was 
amplified at each time point during AZD5582 treatment and these were 
both phylogenetically similar to sequences found before ART treat-
ment. Taken together, these results indicate that AZD5582 induced 
virus reactivation from a diverse population of cells, some of which 
may be clonally expanded25,26.
We quantified cell-associated SIV RNA and SIV DNA in resting CD4+ 
T cells sorted from SIV-infected ART-suppressed rhesus macaques 
treated or not with AZD5582. Cell-associated SIV RNA levels in resting 
CD4+ T cells isolated from lymph nodes were significantly higher in 
macaques who received ten doses of AZD5582 compared with controls 
(P = 0.0148) (Fig. 3e). A similar trend was observed in resting CD4+ T cells 
isolated from the spleens of a subgroup of six macaques that were 
euthanized. Levels of cell-associated SIV DNA in resting CD4+ T cells 
were similar in each compartment across groups (Fig. 3e). To further 
understand whether latency reversal induced by AZD5582 resulted in a 
perturbation of the overall level of infected CD4+ T cells, we performed 
longitudinal measurements of cell-associated SIV DNA in total (rather 
than resting) CD4+ T cells isolated from lymph nodes and blood as 
well as quantitative viral outgrowth assays using CD4+ T cells from 
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Fig. 2 | AZD5582 induces HIV RNA expression in resting CD4+ T cells from 
tissues of HIV-infected ART-suppressed BLT mice. a, BLT mice were infected 
with HIV-1JR-CSF. After 10 weeks of ART treatment, mice received vehicle control 
or AZD5582. FTC, emtricitabine; RAL, raltegravir; TDF, tenofovir disoproxil 
fumarate. b, HIV RNA copies per ml−1 of plasma of HIV-infected ART-treated BLT 
mice before treatment with vehicle control (left; blue lines) or AZD5582 (right; 
red lines). Two independent experiments were performed (left, n = 6 mice per 
group; right, n = 4 mice per group). Grey shading, period of ART administration. 
c, Plasma HIV RNA levels in HIV-infected ART-suppressed mice from b treated 
with vehicle control or AZD5582. d, HIV viral RNA (vRNA) levels in resting CD4+ 
T cells isolated from the bone marrow (BM), thymic organoid (Org), lymph 
nodes (LN), spleen, liver and lung of control or AZD5582-treated mice (cells 
pooled from n = 6 mice per group for each tissue) were analysed in triplicate. 
Data are mean ± s.e.m. Statistical significance was determined using a two-
sided Student’s t-test. e, Cell-associated HIV RNA copies in the blood (n = 6), 
female reproductive tract (n = 6) and brain (n = 3). PBMCs, peripheral-blood 
mononuclear cells. Statistical significance was determined using a two-sided 
Mann–Whitney test (peripheral-blood mononuclear cells and female 
reproductive tract) or Student’s t-test (brain). Colours indicate samples from 
the same mice. Data are mean ± s.e.m.
activation and inflammation21 (Supplementary Table 6). Together, these 
results demonstrate that AZD5582 does not cause generalized toxicity 
or activation of the immune system in the BLT model.
Latency reversal in rhesus macaques
We next evaluated the latency-reversal activity of AZD5582 in 21 
MamuB*08− and MamuB*17− rhesus macaques infected with 
SIVmac239 and treated with a potent ART regimen comprising 
tenofovir diso-proxil fumarate, emtricitabine and dolutegravir 
initiated 8 weeks after 
Data Fig. 6a–c). Despite the high level of virus reactivation induced by 
AZD5582, these experiments did not reveal a consistent reduction in the 
total or replication-competent SIV reservoir compared with controls.
Pharmacodynamics in rhesus macaques
Pharmacological target engagement of the ncNF-κB pathway was 
confirmed by western blot analysis of the degradation of p100 to p52 
in lymph-node mononuclear cells after in vivo exposure to AZD5582 
(Extended Data Fig. 4c) and in splenocytes treated ex vivo with AZD5582 
(Extended Data Fig. 4d–g). Transcriptomic profiling of CD4+ T cells 
from the peripheral blood and lymph nodes isolated from AZD5582-
treated rhesus macaques showed a distinct effect of AZD5582 on gene 
expression based on principal component (Fig. 4a) and DAVID pathway 
(Extended Data Fig. 7a) analyses. Enrichment of NF-κB targets after 
AZD5582 treatment was demonstrated by gene-set enrichment analysis 
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Fig. 3 | AZD5582 induces SIV RNA expression in the plasma and lymph nodes 
of ART-suppressed SIV-infected rhesus macaques. a, Experimental design 
during AZD5582 treatment phase. Three rhesus macaques received three 
doses of AZD5582 and were euthanized 48 h after the last dose. Nine rhesus 
macaques received 10 doses of AZD5582 and 3 were euthanized 48 h after the 
last dose. The first dose of AZD5582 was administered after 55–67 weeks of ART 
(3-dose group, 55 weeks; 10-dose group, 55–67 weeks). Four control rhesus 
macaques received a weekly placebo infusion; 2 were euthanized 48 h after 3 
infusions and 2 were euthanized 48 h after 10 infusions. Five control macaques 
received ART only. b, Plasma SIV RNA levels in the 21 SIV-infected rhesus 
macaques before treatment with AZD5582 (left, n = 12) and equivalent time 
period for controls (right, n = 9). b–d, Grey shading represents the period of 
ART administration. c, Plasma SIV RNA levels in ART-suppressed SIV-infected 
rhesus macaques during AZD5582 treatment (left, n = 12) and the equivalent 
time period for controls (right, n = 9). d, Individual representation of plasma 
SIV RNA levels in the five rhesus macaques that experienced on-ART viraemia 
during AZD5582 treatment. e, Cell-associated SIV RNA (left) and SIV DNA 
(right) levels in resting CD4+ T cells isolated from lymph nodes, peripheral 
blood (PB), spleen and bone marrow of AZD5582-treated (red) and control 
(blue) ART-suppressed SIV-infected rhesus macaques. Resting CD4+ T cells 
were analysed from AZD5582-treated rhesus macaques 48 h after receiving 3 
doses (D3; lymph nodes, peripheral blood and spleen, n = 3) or 10 doses (D10; 
lymph nodes, n = 7; peripheral blood, n = 9; spleen, n = 3; bone marrow, n = 6) of 
AZD5582. Resting CD4+ T cells were analysed from control rhesus macaques  
(C; lymph nodes and peripheral blood, n = 9; spleen, n = 4; bone marrow, n = 5) at 
equivalent time points. Open symbols indicate AZD5582-treated rhesus 
macaques with on-ART viraemia. Statistical significance was determined with a 
two-sided Mann–Whitney U-test. Horizontal lines represent the median.
(GSEA) (Fig. 4b; a heat map of differentially expressed gene targets of 
NF-κB is shown in Extended Data Fig. 7b). The hallmark ncNF-κB sig-
nalling genes NFKB2 and RELB were significantly upregulated in CD4+ 
T cells from the peripheral blood and lymph nodes after AZD5582 treat-
ment, whereas cNF-κB signalling molecules were mostly unaffected 
except for the inhibitor NFKBIA (Fig. 4c). The baculoviral IAP repeat-
containing 3 (BIRC3) gene, which encodes cIAP2 and regulates both 
the cNF-κB and ncNF-κB pathways, was also significantly upregulated 
in CD4+ T cells from the peripheral blood and lymph nodes (Fig. 4c). 
Notably, activation of ncNF-κB signalling genes was evident in rhesus 
macaques with and without on-ART viraemia of more than 60 copies per 
ml (Fig. 4c and Extended Data Fig. 7c) and GSEA showed similar changes 
in overall gene expression when AZD5582-treated rhesus macaques 
were grouped according to the presence or absence of on-ART viraemia 
of more than 60 copies per ml (Supplementary Table 8), suggesting 
that the lack of a virological response measured by the standard viral 
load assay was not due to compromised target engagement.
We next used an ultrasensitive assay to measure SIV RNA in plasma, 
comparing 2–3 baseline time points during ART in the 4 weeks before 
AZD5582 treatment (when plasma SIV RNA was less than 60 copies per 
ml in all rhesus macaques using the standard viral load assay) and 3–4 
time points during AZD5582 treatment (Extended Data Fig. 8a). We 
found significantly higher plasma SIV RNA values during the period 
of AZD5582 treatment compared with pre-treatment (Extended Data 
Fig. 8b, P = 0.008), with 8 out of 12 rhesus macaques demonstrating 
≥2 SIV RNA measurements above the median of their baseline values. 
This group of eight rhesus macaques with evidence of latency rever-
sal induced by AZD5582 could be segregated from the four rhesus 
macaques with unchanged viral loads based on two parameters: higher 
levels of plasma SIV RNA immediately before ART initiation and SIV 
DNA in peripheral CD4+ T cells before AZD5582 treatment (P = 0.004 
for each) (Extended Data Fig. 8c).
Safety and immune effects in rhesus macaques
The potential for AZD5582 toxicity in SIV-infected ART-suppressed 
rhesus macaques was examined and transient increases in liver enzymes 
(aspartate aminotransferase and γ-glutamyltransferase) were observed 
(Extended Data Fig. 9a). Total white-blood cell counts were decreased 
in all rhesus macaques 48 h after the first dose of AZD5582 but returned 
to normal levels when measured before the second dose and over 
time (Extended Data Fig. 9b). After the seventh and eighth doses, one 
macaque experienced a reaction characterized by fever, emesis, fatigue 
and lack of appetite, and had elevated liver enzyme and creatinine levels 
and bandaemia as shown by laboratory examination. All abnormalities 
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Fig. 4 | AZD5582 specifically activates the ncNF-κB 
pathway in SIV-infected ART-suppressed rhesus 
macaques without generalized T cell activation.  
a–c, Gene expression in CD4+ T cells from the 
peripheral blood and lymph nodes of SIV-infected 
ART-suppressed rhesus macaques before and after 
treatment with AZD5582 (n = 6 for both lymph  
nodes and peripheral blood; for each, n = 3 for 3 
doses of AZD5582 and n = 3 for 10 doses of AZD5582). 
a, Principal component (PC) analyses of the 
transcriptomes of CD4+ T cells from the peripheral 
blood (top) and lymph nodes (bottom), before (grey) 
and after (red) treatment with AZD5582. Ellipses, 
two standard deviations. b, GSEA plots of NF-κB-
induced genes in CD4+ T cells from the peripheral 
blood (top) and lymph nodes (bottom). Gene set: 
‘hallmark TNF signalling via NF-κB’ (MSigDB). 
NES, normalized enrichment score. c, Heat map of 
cNF-κB (top) and ncNF-κB (bottom) pathway gene 
expression. Colour scale, log2-transformed fold 
changes after AZD5582 treatment compared with 
before treatment. Genes that are differentially 
expressed after treatment with AZD5582 in the 
peripheral blood (asterisks) or lymph nodes 
(daggers) CD4+ T cells are highlighted.  
d, e, Expression of activation markers in CD4+ (d)  
and CD8+ (e) T cells in the peripheral blood (top)  
and lymph nodes (bottom) of SIV-infected ART-
suppressed rhesus macaques before treatment with 
AZD5582 and 48 h after the final dose (n = 12, red)  
and control rhesus macaques (n = 9, blue). Statistical 
significance was determined using a two-sided 
Mann–Whitney U-test.
not receive further doses. Notably, weights did not significantly fluctu-
ate over the course of the treatment period (Extended Data Fig. 9c). In 
summary, 97 doses of AZD5582 were administered to 12 SIV-infected 
ART-suppressed rhesus macaques, of which 95 were well-tolerated and 
2 resulted in a mild adverse reaction.
Markers of T cell activation (both CD4+ and CD8+) were assessed 
in AZD5582-treated rhesus macaques and controls, and expression 
of CCR5, HLA-DR and PD-1 on CD4+ T cells from the blood and lymph 
nodes was similar before and after treatment with AZD5582 (Fig. 4d, e). 
Levels of intracellular Ki-67 expression were increased in CD4+ T cells in 
the blood and CD8+ T cells in the blood and lymph nodes after AZD5582 
treatment (Fig. 4d, e). CD8+ T cell expression of HLA-DR was higher in 
the blood after exposure to AZD5582 (Fig. 4e). These results indicate 
that AZD5582 does not induce global CD4+ T cell activation in rhesus 
macaques but the combined pharmacological and virological effects 
may have a stimulatory effect on CD8+ T cells. Longitudinal analyses 
of CD4+ T cell counts and frequencies, CD4+ T cell viability, CD4+ T cell 
subset frequencies and their Ki-67 expression are shown in Extended 
Data Fig. 10a–d. The increased Ki-67 observed within CD4+ T cells after 
AZD5582 treatment may provide a note of caution as the proliferation 
of latently infected memory CD4+ T cells is hypothesized to contribute 
to the maintenance of the viral reservoir over time25,27; however, we did 
not find an increase in infected cells after AZD5582 treatment (Fig. 3e 
and Extended Data Fig. 6).
We next determined whether AZD5582 would impair SIV-specific T cell 
responses in SIV-infected ART-suppressed rhesus macaques, a poten-
tial adverse outcome of treatment that has been suggested for other 
LRAs28. However, the frequency of SIV Gag- or Env-specific CD8+ T cells 
measured by IFNγ ELISPOT did not decrease after AZD5582 treatment 
(Extended Data Fig. 10e), and CD8+ T cell polyfunctionality and prolifera-
tive responses were largely unaffected by AZD5582 treatment ex vivo, 
with the exception of IL-2+IFNγ+TNF+ triple-positive cells, which were 
slightly reduced (P = 0.0476) (Extended Data Fig. 10f, g). Furthermore, 
longitudinal assessment of plasma levels of inflammatory cytokines and 
chemokines did not reveal any marked changes induced by AZD5582 
(Extended Data Fig. 10h). Overall, our work in the rhesus macaque model 
indicates that AZD5582 treatment is safe in most macaques and can 
induce appreciable increases in plasma SIV RNA as well as SIV RNA expres-
sion in resting CD4+ T cells from the lymph nodes during ART.
Discussion
Eradication of HIV infection after prolonged viral suppression is the 
focus of intense research and latency reversal has been a cornerstone 
of this effort. LRAs have been widely recognized as important (but 
previously mostly theoretical) tools to induce HIV expression in 
resting CD4+ T cells in humans. Future clinical applications of HIV 
cure strategies must be relevant to the majority of people living with 
HIV for whom the treatments of the Berlin and London patients29,30 
(whose non-HIV life-threatening haematological malignancies war-
ranted aggressive, toxic therapies) pose an unacceptable level of risk. 
Therefore, LRAs must be identified that are highly effective but have 
minimal side effects. Here, we used two different but highly comple-
mentary animal models31 to show that treatment with AZD5582 had 
minimal and transient side effects but resulted in significant increases 
in HIV and SIV RNA levels both in the plasma and in resting CD4+ T cells 
isolated from all analysed tissues from BLT mice and from the lymph 
nodes of macaques. Our results provide in vivo evidence of systemic 
HIV and SIV latency reversal from resting CD4+ T cells. The concord-
ance between the results obtained in two fundamentally different 
animal models highlights the robust and reproducible nature of the 
effect of AZD5582 on HIV and SIV reservoirs. The fact that there is 
little toxicity associated with the use of AZD5582 strongly suggests 
that activators of the ncNF-κB pathway may be well-suited for HIV 
eradication approaches in humans.
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Methods
Experimental design
The purpose of this study was to determine the efficacy of the SMAC-
mimetic AZD5582 as an HIV and SIV LRA in vivo. To this end, two animal 
models of HIV-1 infection were used: the HIV-infected BLT humanized 
mouse model and the SIV-infected rhesus macaque (Macaca mulatta) 
nonhuman primate (NHP) model. In each model, animals were infected 
with HIV-1 or SIV and viraemia was durably suppressed with ART. 
AZD5582 was administered to infected ART-suppressed animals that 
were then assessed for changes associated with the reactivation of the 
viral reservoir. Mice were maintained under specific-pathogen-free 
conditions by the Division of Comparative Medicine at the University 
of North Carolina, Chapel Hill. Mouse experiments were conducted in 
accordance with NIH guidelines for the housing and care of laboratory 
animals and in accordance with protocols reviewed and approved by the 
Institutional Animal Care and Use Committee (IACUC) at the University 
of North Carolina, Chapel Hill. Healthy rhesus macaques for pharma-
cokinetic studies were housed at GlaxoSmithKline and all procedures 
were conducted in accordance with the GlaxoSmithKline policy on the 
care, welfare and treatment of laboratory animals and were reviewed 
by the IACUC at GlaxoSmithKline. Rhesus macaques infected with 
SIV were housed at the Yerkes National Primate Research Center and 
treated in accordance with Emory University and Yerkes National Pri-
mate Research Center IACUC regulations (PROTO201800308). Animal-
care facilities are accredited by the US Department of Agriculture and 
the Association for Assessment and Accreditation of Laboratory Animal 
Care International.
Preparation of Jurkat HIV–luciferase cell clones
Cell clones Jurkat-C16 and Jurkat-I15 were prepared by infecting Jur-
kat cells ( Jurkat clone E6-1 cells, American Type Culture Collection 
TIB-152, authenticated by morphological identification and virus-
susceptibility profiles, tested for mycoplasma by the supplier) with 
a full-length, infectious HIV-1NL4-3-based virus engineered to express 
a luciferase reporter in place of the HIV-1 nef gene (NLCH-Luci). The 
Jurkat-N6 cell clone was generated using the same virus as described 
above with an additional mouse heat-stable antigen (HSA) reporter 
located just downstream of the luciferase open-reading frame and 
separated by a T2A element (NLCH-Luci-HSA). NLCH, provided by 
R. Swanstrom, is the parent molecular infectious clone used to make 
the Jurkat clones and is a modification of HIV-1NL4-3 (GenBank U26942) 
in which flanking sequences were removed. All viruses were derived 
by transfection of human embryonic kidney 293 cells (HEK 293T, 
European Collection of Authenticated Cell Cultures, authenticated 
by morphological identification, tested for mycoplasma by the sup-
plier) with 1 μg of the HIV-1NL4-3-derived infectious molecular plasmid 
DNA using the FuGENE HD Transfection reagent (Promega) according 
to the manufacturer’s recommendations. Supernatants were collected 
48 h after transfection, passed through a 0.2-μm filter, and used to 
infect wild-type Jurkat cells. After infection, cells expressing high levels 
of HIV-encoded mouse HSA were removed using biotin-labelled rat 
anti-mouse CD24 antibody (clone M1/69, BD Biosciences) that was 
adsorbed to streptavidin-labelled magnetic Dynabeads M-280 (Life 
Technologies) according to the manufacturer’s recommendations. 
Negatively selected HIV-infected Jurkat cells were then limit-diluted 
to 0.5 cells per well in 96-well plates, and individual cell clones were 
expanded for 2–4 weeks in culture in the presence of 500 nM efavirenz. 
Clones were profiled for baseline reporter level and responsiveness to 
benchmark LRAs, with C16, I15 and N6 representing the most quiescent 
but inducible clones that were obtained.
Cell culture and Jurkat HIV–luciferase assay
Jurkat HIV–luciferase clones were maintained in Roswell Park Memorial 
Institute (RPMI) 1640 medium (Gibco, Life Technologies) containing 
10% (v/v) fetal bovine serum (FBS; SAFC, Sigma-Aldrich), 25 U ml−1 peni-
cillin and 25 U ml−1 streptomycin (Gibco, Life Technologies), and were 
split 1:4 every 3–4 days to maintain a cell density of around 0.3–1 million 
cells per ml. The Jurkat clones were maintained with the addition of 
500 nM efavirenz to the medium. Three Jurkat cell clones (C16, I15 and 
N6), each of which contained one or two integrated HIV proviruses that 
expressed the luciferase reporter gene, were added at equal amounts 
for a total of 5,000 cells per well to 384-well plates containing com-
pound titrations. Dose–response testing was performed on compounds 
dissolved in dimethyl sulfoxide (DMSO; Fisher Scientific) dispensed 
in duplicate serial threefold, 14-point titrations using a D300e Digital 
Droplet Dispenser (Hewlett-Packard) to give final assay concentrations 
ranging from 10 μM to 2.1 pM in 50 μl of medium with a final concentra-
tion of 0.5% DMSO (v/v). Cells and compound were incubated at 37 °C 
for 48 h, unless otherwise indicated, followed by the addition of 20 μl 
of Steady-Glo Luciferase (Promega). Luminescence resulting from 
the induction of virally expressed luciferase was measured using an 
EnVision 2102 Multilabel Plate Reader (Perkin Elmer). Dose–response 
relationships were analysed with GraphPad Prism (v.6) using a four-
parameter logistic regression model to calculate the concentration of 
compound that provides the half-maximal response and the maximal 
percentage activation compared to the vehicle control.
Immunoblot analyses
For the immunoblot assays, 10 μg of cell lysate was loaded per well into 
4–20% Tris-Glycine SDS–PAGE gels. Proteins from the SDS–PAGE gels 
were transferred to Turbo Midi PVDF Transfer Packs (BioRad) using the 
‘Mixed MW’ protocol for one Midi Format Gel (constant 2.5 A up to 25 V, 
for 7 min) of the Trans-Blot Turbo Transfer System (BioRad) with pre-
made Trans-Blots according to the manufacturer’s instructions. After 
transfer, PVDF membranes were blocked in 5% bovine serum albumin 
(BSA) in 1× Tris-buffered saline (TBS) (BioRad) with 0.1% Tween-20 for 
1 h at room temperature with gentle rocking. Primary antibodies were 
added and incubated overnight at 4 °C (anti-cIAP1, 1:1,000 (Abcam); 
anti-p100/p52, 1:1,000 (Cell Signaling Technology); anti-IκBα, 1:1,000 
(Cell Signaling Technology); anti-cIAP2, 1:1,000 (Abcam); and anti-
actin-HRP conjugate, 1:30,000 (Abcam). After staining with primary 
antibodies, the membrane was washed three times with 1× TBS and 
0.1% Tween-20, 10 min each wash. After washing, the membrane was 
incubated in 5% BSA in 1× TBS and 0.1% Tween-20 with the appropriate 
secondary antibody for 2 h at room temperature. After staining with 
secondary antibodies, the membrane was washed twice for 10 min 
with 1× TBS and 0.1% Tween-20 followed by a 10-min wash with 1× TBS. 
The membrane was then patted dry with filter paper and an image was 
captured of the undeveloped membrane on a ChemiDoc MP Imaging 
System using Image Laboratory software (v.6.0.1, BioRad). Sufficient 
ECL reagent (GE Healthcare) was used to cover the membrane and a 
series of images was taken with increasing exposure times until the 
luminescence from the developed membrane saturated the image. The 
developed membrane was then washed 3 times with 1× TBS for 5 min to 
remove the residual ECL reagent and then stored at 4 °C in sufficient 
1× TBS to submerse the entire membrane. Densitometry of images of 
the developed membrane was then carried out using Image Laboratory 
software (v.6.0.1, BioRad). Some membranes were stripped for 1 min 
with One Minute Plus Western Blot Stripping Buffer (GM Biosciences) 
and then washed 3 times for 10 min with 1× TBS. The stripped mem-
branes were then blocked in 5% BSA in 1× TBS and 0.1% Tween-20 for 
1 h and re-probed overnight with a new primary antibody. To normalize 
samples for loading a 1:20,000 dilution of β-actin (Abcam) was run on 
the stripped membranes.
Target gene RT–qPCR
We treated 2 million normal donor CD4+ T cells with a range of concen-
trations of AZD5582. Total RNA was isolated using the RNEasy Mini kit 
(Qiagen) according to the manufacturer’s instructions. The following 
TaqMan primer probe sets were sourced from Applied Biosystems: 
Hs00985031_g1 (BIRC3), Hs00174517_m1 (NFKB2) and Hs02800695 
(HPRT1). TaqMan-based quantitative PCR with reverse transcription 
(RT–qPCR; Fast Virus 1-Step Master Mix, Applied Biosystems) was used 
to amplify host genes of interest and acquire the signal on a QuantStu-
dio 3 Real-Time PCR thermocycler (ThermoFisher). Gene expression 
was normalized to HPRT1 and the comparative threshold cycle (Ct) 
method (ΔΔCt) was used for relative quantification of gene expression. 
Relative quantification was analysed by QuantStudio 3 Real-Time PCR 
System software (v.1.4.3, ThermoFisher).
HIV quantitative viral outgrowth
All human peripheral-blood mononuclear cell (PBMC) samples were 
obtained under a specimen procurement protocol reviewed and 
approved by the University of North Carolina Biomedical Institutional 
Review Board and the McGill University Health Centre Ethical Review 
Board. Informed consent was obtained from all participants. Human 
PBMCs for quantitative viral outgrowth were obtained using continu-
ous flow leukapheresis. Resting CD4+ T cells were isolated and virus 
outgrowth assays were performed as previously described32,33 with 
some modifications. In brief, 20–50 × 106 highly purified resting CD4+ 
T cells were stimulated with phytohaemagglutinin, IL-2 (60 U ml−1) and 
irradiated PBMCs from a seronegative donor, or with 100 nM AZD5582, 
335 nM vorinostat or 0.003% DMSO (vehicle control) in limiting dilu-
tions for 24 h. Cultures were washed to remove drugs and CCR5high, 
CD8-depleted, phytohaemagglutinin-stimulated PBMCs from an unin-
fected donor were added twice to amplify virus outgrowth. Culture 
supernatants were assayed for HIV p24 expression by ELISA on day 15 
and confirmed on day 19. A maximum-likelihood method was used to 
estimate the frequency of inducible virus and is reported as infectious 
units per million34.
RNA-sequencing analysis of human cells
Total CD4+ T cells were isolated from PBMCs of four ART-treated avirae-
mic patients by negative selection (EasySep Human CD4+ T Cell Enrich-
ment Kit, StemCell) according to the manufacturer’s instructions. Dead 
cells and other debris were removed using a Dead Cell Removal Kit 
(Miltenyi Biotec) according to the manufacturer’s instructions. Cells 
from each patient were treated with 0.05% DMSO, 100 nM AZD5582 
or 25 nM ingenol B and collected 2 h, 6 h and 24 h after exposure. RNA 
was isolated from the collected cells using AllPrep DNA/RNA Mini Kit 
(Qiagen). Then, 200 ng of RNA from each sample was checked for qual-
ity using an Agilent Bioanalyzer; RNA-integrity number scores were 
typically >9.0, suggesting that high-quality RNA was obtained. These 
total RNA samples were then processed into stranded, mRNA libraries 
using the KAPA library preparation kit (KAPA BioSystems, F. Hoffmann-
La Roche). The concentrations of the final libraries were checked by 
Qubit (Thermo Fisher) and the fragment size distribution (mean size, 
359 bp) was analysed with a BioAnalyzer HS-DNA chip (Agilent). Samples 
were then sequenced using an Illumina Hiseq 4000 sequencer using 
a paired-end 50-bp by 50-bp run. Samples were successfully demul-
tiplexed and then quality assurance and quality control was carried 
out using FASTQC (v.0.11.1) (https://www.bioinformatics.babraham.
ac.uk/projects/fastqc/).
Raw reads were mapped to the human genome and transcriptome 
(GRCh38.p7) using STAR35 and Salmon (v.0.7.2)36. Data were normal-
ized and analysed for changes in gene expression using the DESeq2 
package37 in R. P values were adjusted for multiple testing using a false-
discovery rate using the Benjamini–Hochberg method38. Data were 
analysed both jointly and within each treatment compared with the 
vehicle control. Differential expression of outliers was assessed and 
found to have a non-significant overall effect. Thresholds applied to 
call a significant response were mean log2-transformed fold change 
>1 and adjusted P < 0.05. Graphs and summary tables were built in R
using ggplot. Gene-set enrichment was performed using GSEA (v.2.2.3)
and GO analysis (GO PANTHER v.11.1)39. Results shown are the mean 
responses of the four donors tested.
Generation and maintenance of BLT mice
BLT mice were prepared as previously reported18,40,41. In brief, a 1–2-mm 
piece of human liver tissue was sandwiched between two pieces of 
autologous thymus tissue (Advanced Bioscience Resources) under 
the kidney capsule of sublethally irradiated (200 cGy) 12–15-week-
old female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG; The Jackson Labora-
tory) mice. After implantation, mice were transplanted intravenously 
with CD34+ haematopoietic stem and progenitor cells isolated from 
autologous human liver tissue. Human immune cell reconstitution 
was monitored in the peripheral blood of BLT mice by flow cytometry 
every 3–4 weeks21. For the study that examined the effect of AZD5582 
administration on T cell activation, the mean weight of the mice used 
was 26.88 g and they were approximately 1 year of age at the initia-
tion of the study. For the study that examined the effect of AZD5582 
administration on plasma and tissue viraemia during ART suppres-
sion, the mean weight of the mice used was 23.14 g and the mice were 
approximately 7 months old at the initiation of the study. Mice were 
randomized for assignment to either experimental or control groups 
(https://www.random.org/).
HIV infection of BLT mice
Stocks of HIV-1JR-CSF were prepared as follows. The proviral clone was 
transfected into HEK293T cells using Lipofectamine 2000 (Invitro-
gen) following the manufacturer’s protocols. Viral supernatant was 
collected 48 h after transfection. Viral supernatant was titrated by 
infecting TZM-bl cells (NIH AIDS Reagent Program, authenticated by 
morphological identification and virus-susceptibility profiles, tested 
for mycoplasma by the supplier) at multiple dilutions. Virus-containing 
medium was removed the next day and replaced with fresh Dulbecco’s 
modified Eagle medium (DMEM; ThermoFisher) plus 10% FBS and the 
incubation continued for 24 h. The cells were fixed and stained with 
5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside and blue cells were 
counted directly to determine infectious particles per ml. Each titre of 
these viral stocks was performed in triplicate and at least two different 
titre determinations were performed for each virus stock. Exposure of 
BLT mice to HIV-1JR-CSF was conducted by tail vein injection with 3 × 10
4 
tissue culture infectious units of virus. Plasma viral load in peripheral 
blood of infected mice was monitored longitudinally by RT–qPCR using 
TaqMan RNA to-CT 1-step kit (Applied Biosystems). The sequences
of the forward and reverse primers and the TaqMan probe for PCR 
amplification and detection of HIV gag RNA were: 5′-CATGTTTTCA 
GCATTATCAGAAGGA-3′, 5′-TGCTTGATGTCCCCCCACT-3′ and 5′-FA 
M-CCACCCCACAAGATTTAAACACCAT-GCTAA-Q-3′, respectively. For 
viral load analysis, 40 μl of plasma was collected and analysed with a 
sensitivity of 350 copies per ml. All samples were run and analysed on 
an ABI 7500 Fast Real Time PCR System (Applied Biosystems).
SIV infection of NHPs
In total, 21 male and female Indian rhesus macaques, 3–6 years of age, 
with the exclusion of MamuB*08+ and MamuB*17+ macaques, were 
included in this study (Supplementary Table 7). Rhesus macaques 
were infected intravenously with 3 × 103 TCID50 (50% tissue culture 
infectious dose) of SIVmac239. The SIVmac239 stock was titrated in vitro 
for viral infectivity by standard end-point titration on CEMx174 cells. 
The TCID50 was calculated as previously described
42. Standard SIVmac239 
plasma viral-load quantification was performed regularly throughout 
the study and three times per week during the AZD5582 treatment 
period in the Translational Virology Core Laboratory of the Emory 
Center for AIDS Research using a standard qPCR assay (limit of detec-
tion of 60 copies per ml of plasma) as previously described43. Ultra-
sensitive SIVmac239 plasma viral-load quantification (limit of detection 
of 3 copies per ml of plasma) was performed for 2–3 time points before 
AZD5582 treatment and 3–4 time points during AZD5582 treatment as 
previously described44,45.
ART and AZD5582 treatment of BLT mice and NHPs
ART was administered to BLT mice using irradiated Teklad chow con-
taining emtricitabine (1,500 mg kg−1), tenofovir disoproxil fumarate 
(1,560 mg kg−1) and raltegravir (600 mg kg−1) (Research Diets). Both 
the AZD5582 and the vehicle control (10% sterile captisol dissolved in 
sterile distilled water) were prepared fresh for each administration. 
AZD5582-2HCl was obtained from ChemieTek and dissolved at 5 mg ml−1 
in sterile distilled water (Gibco, Life Technologies) containing 10% 
captisol β-cyclodextrine sulfobutyl ethers sodium salts (Cydex Phar-
maceuticals). AZD5582 was administered by intraperitoneal injection 
at a dose of 3 mg kg−1.
Rhesus macaques were treated with a potent 3-drug ART regimen 
initiated 56 days after infection that consisted of 2 reverse transcriptase 
inhibitors, tenofovir disoproxil fumarate (5.1 mg ml−1) and emtricitabine 
(40 mg ml−1) plus the integrase inhibitor dolutegravir (2.5 mg ml−1). ART 
was administered once daily at 1 ml kg−1 body weight via the subcuta-
neous route. Peak plasma viral load (measured by the standard assay) 
and plasma viral load before LRA intervention (as measured by the 
ultrasensitive assay) were controlled for when allocating macaques 
into experimental groups. In total, 12 rhesus macaques were treated 
with AZD5582 and 9 rhesus macaques served as controls. AZD5582 was 
infused weekly intravenously at 0.1 mg kg−1. Three rhesus macaques 
received 3 doses of AZD5582 and were euthanized 48 h after the last 
dose. Nine rhesus macaques received 10 doses of AZD5582 and 3 
macaques were euthanized 48 h after the last dose. Among the con-
trol rhesus macaques, 4 macaques received a weekly placebo infusion, 
2 macaques were euthanized 48 h after 3 infusions and 2 macaques 
were euthanized 48 h after 10 infusions. The remaining five control 
macaques received ART only.
Resting CD4+ T cell enrichment
Human resting CD4+ T cells were enriched from total cells isolated 
from BLT mouse tissues as follows. Each tissue from each mouse was 
processed individually and then tissues were pooled for immunomag-
netic sorting. Each pooled tissue was first enriched for human cells 
with the EasySep Mouse/Human Chimera Kit (Stem Cell Technolo-
gies) and then for resting CD4+ T cells with a human custom selection 
kit that included the following antibodies: CD8, CD14, CD16, CD19, 
CD20, CD36, CD56, CD123, glycophorin A, CD66b, CD25 and HLA-DR 
(all Stem Cell Technologies). Flow cytometry was performed before 
and after the enrichment to confirm the efficacy of the sort and purity 
of the sorted samples.
Resting CD4+ T cells from rhesus macaques were isolated from the 
peripheral blood, bone marrow, lymph node and spleen. Before sorting, 
CD4+ T cells were enriched using magnetic beads and column purifi-
cation (Miltenyi Biotec). Enriched CD4+ T cells were then stained with 
previously determined volumes of the following fluorescently conju-
gated antibodies: CD3 AF700 (clone SP34-2), CD8 APC-Cy7 (clone SK1), 
CD69 PE-CF594 (clone FN50), HLA-DR PerCP-Cy5.5 (clone G46-6) (all 
from BD Bioscience) and CD4 BrilliantViolet (BV)650 (clone OKT4) 
and CD25 PE-Cy7 (clone BC96) (both from Biolegend). Resting CD4+ 
T cells were defined as CD3+CD4+CD8−CD69−CD25−HLA-DR−. Sorting 
was performed on a FACSAria LSR II (BD Biosciences) equipped with 
FACSDiva software.
Plasma cytokine and chemokine analysis
Human plasma cytokine and chemokine analysis in BLT mice was per-
formed by the University of North Carolina, Chapel Hill Center for AIDS 
Research Virology Core Laboratory. Plasma was tested undiluted in sin-
gle wells using a Milliplex MAP kit (Millipore, HCYTMAG-60K-PX41) on a 
Luminex MAGPIX instrument. The following markers were tested: EGF, 
eotaxin, FGF-2, FLT-3L, fractalkine, G-CSF, GM-CSF, GRO, IFNα2, IFNγ, 
IL-1α, IL-1β, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p40, 
IL-12p70, IL-13, IL-15, IL-17A, IP-10, MCP-1, MCP-3, MDC, MIP-1α, MIP-1β, 
PDGF-AA, PDGF-AB/BB, RANTES, sCD40L, TGFα, TNF, TNFβ and VEGF.
Rhesus macaque plasma levels of proinflammatory cytokines and 
chemokines were evaluated using the NHP MSD V-Plex assay systems 
developed by MesoScale Discovery. The two validated kits used were 
the V-PLEX Plus Proinflammatory Panel 1 NHP Kit (K15056D) that evalu-
ates IFNγ, IL-10, IL-1β, IL-2, IL-6 and IL-8, and a custom Chemokine NHP 
Kit that evaluates IP-10, MCP-1 and MIP-1β (K15055G). The manufac-
turer-provided protocol was followed with a few modifications. As the 
plasma samples were infectious, Triton X-100 at a final concentration 
of 1% was added not only to the subject samples but also to the assay 
diluents provided with the MSD kit before use. Calibration standards 
were reconstituted according to the protocol provided with the assay 
diluent that had the Triton X-100 added to it so that all standards and 
samples had the same components present. Plasma (60 μl) was diluted 
twofold with assay diluent and then 50 μl of the diluted sample was 
added to the assay plate along with 50 μl of the calibrator according 
the manufacturer’s protocol. The plate was then covered and incubated 
on a shaker for 2 h. After the 2-h incubation, plates were washed at least 
6× with the supplied wash buffer and then 25 μl of detection antibodies 
was added according to the kit protocol. Subsequently, the plate was 
covered and incubated on a shaker for 2 h at room temperature. After 
the detection incubation was finished, plates were then washed 6× and 
150 μl of 2× read buffer was added to each well and plates were analysed 
on the Sector s600 MSD plate reader. Data analysis was performed 
using the MSD Discovery Workbench analysis software.
Cell-associated HIV RNA quantification in BLT mice
For tissue RNA analysis, RNA was extracted using QIAamp viral RNA 
columns (Qiagen) according to the manufacturer’s protocol includ-
ing an optional treatment with RNase-free DNase and analysed using 
one-step reverse-transcriptase qPCR (ABI custom TaqMan Assays-
by-Design)46. Known quantities of HIV gag RNA standards were run 
in parallel, creating a standard curve for HIV gag and sample RNA was 
quantified by extrapolation from the standard curve. All samples were 
run and analysed on an ABI 7500 Fast Real-Time PCR System (Applied 
Biosystems). Owing to the relatively low number of human cells found 
in the brain, HIV RNA levels were quantified for only three vehicle con-
trol- and three AZD5582-treated mice.
Immunohistochemical analysis in BLT mice
Tissues for immunohistochemical analysis were collected from BLT 
mice and fixed in 10% formalin for 16–24 h at 4 °C. Samples were then 
embedded in paraffin, cut into 5-μm sections and mounted onto poly-
l-lysine-coated glass slides. After paraffin removal, antigen retrieval 
(DIVA Decloaker, Biocare Medical) and blocking of nonspecific immu-
noglobulin-binding sites (Background Sniper, Biocare Medical), tissue 
sections were stained with anti-cIAP1 antibody (R&D Systems) overnight 
at 4 °C. To detect cIAP1, sections were probed with a goat-on-rodent 
HRP polymer (Biocare Medical) and developed with diaminobenzi-
dine (ImmPact DAB Peroxidase Substrate, Vector Laboratories). As 
an isotype control, tissue sections were stained with polyclonal goat 
IgG (R&D Systems) negative control antibodies. Tissue sections were 
imaged with a Nikon Eclipse Ci microscope using Nikon Elements BR 
software (v.4.30.01) and a Nikon Digital Sight DS-Fi2 camera.
Serum chemistry analysis in mice
After treatment with AZD5582 for 24 h, serum chemistry analysis 
in female 20-week-old BALB/cJ mice (The Jackson Laboratory) was 
performed by the University of North Carolina, Chapel Hill Animal 
Histopathology Core Laboratory of the Lineberger Comprehensive 
Cancer Center. All clinical chemistry was performed on an Alfa Wasser-
mann Vet Axcel analyser using Alfa Wassermann reagents. Automated 
assays for each analyte were as follows and performed according to the 
manufacturer’s instructions: alkaline phosphatase, Tietz-optimized 
Bowers and McComb assay; aspartate aminotransferase, Henry modifi-
cation of Karmen’s assay; alanine aminotransferase, Henry modification 
of Wroblewski and LaDue assay; creatinine, Jaffe reaction; blood urea 
nitrogen, enzymatic assay; albumin, Doumas and Briggs modification 
of the bromcresol green dye method; amylase, based on the use of 
chromogenic 2-chloro-p-nitrophenol linked with maltotriose; calcium, 
calcium-arsenazo assay phosphorus, based on the method of Daly 
and Ertingshausen with modifications by Armador and Urban; total 
bilirubin, Walters and Gerarde modification of the DMSO method; total 
protein, modification of Weichselbaum’s biuret reagent.
Immunophenotyping of BLT mice by flow cytometry
Immunophenotyping was performed on peripheral-blood samples 
collected longitudinally and at study end point, on blood and mono-
nuclear cells isolated from the tissues of BLT mice. All flow cytometry 
data were collected on either BD LSR Fortessa or BD FACSCanto instru-
ments using BD FACSDiva software (v.6.1.3) and data were analysed with 
FlowJo software (v.10.4.2). Antibodies used for longitudinal monitoring 
of human cells in peripheral blood include anti-CD45 APC (clone HI30, 
BD Biosciences), anti-CD3 FITC (clone HIT3a, BD Biosciences), anti-CD4 
PE (clone RPA-T4, BD Biosciences) and anti-CD8 PerCP (clone SK1, BD 
Biosciences). Flow cytometry gating for the expression of lineage-
specific antigens on human leukocytes was performed as follows. Step 
1, forward- and side-scatter properties were used to set a live-cell gate. 
Step 2, live cells were then analysed for expression of the human pan-
leukocyte marker CD45. Step 3, human leukocytes were then analysed 
for human CD3+ T cells. Step 4, T cells were analysed for human CD4 
and CD8 expression (Supplementary Fig. 2a).
At collection, peripheral blood and cells isolated from each individual 
tissue were stained with antibodies to detect human CD45, CD3, CD4, 
CD8, CD38 (anti-CD38 APC, clone HB7, BD Biosciences) and HLA-DR 
(anti-HLA-DR PE, clone TU36, BD Biosciences) to assess T cell activation. 
The following gating strategy was used. Step 1, forward- and side-scatter 
properties were used to set a live cell gate. Step 2, live cells were then 
analysed for expression of the human pan-leukocyte marker CD45. 
Step 3, human leukocytes were subsequently analysed for human CD3+ 
T cells. Step 4, T cells were analysed for human CD4 and CD8 expression. 
Step 5, either CD4+ or CD8+ T cells were analysed for the expression of 
CD38 and HLA-DR (Supplementary Fig. 2b).
To determine the success of the sort and the purity of the sorted 
human resting CD4+ T cells, the following antibodies were used to ana-
lyse pre-sort and post-sort samples: anti-CD3 BV421 (clone UCHT1, BD 
Biosciences), anti-HLA-DR PerCP (clone L243, BD Biosciences), anti-CD4 
BV605 (clone RPA-T4, BD Biosciences), anti-CD8 APC-Cy7 (clone SK1, 
BD Biosciences), anti-CD25 APC (clone 2A3, BD Biosciences) and anti-
CD45 V500 (clone H130, BD Biosciences). Antibodies used as isotype 
controls: anti-mouse IgG1κ APC (clone MOPC-21, BD Biosciences), anti-
mouse IgG2ακ PerCP (clone X39, BD Biosciences), anti-mouse IgG1κ 
PE (clone MOPC-21, BD Biosciences), anti-mouse IgG1κ PE-Cy7 (clone 
MOPC-21, BD Biosciences) and anti-mouse IgG2ακ FITC (clone G155-178, 
BD Biosciences). Flow cytometry gating was performed as follows. Step 
1, live cells were gated based on forward scatter and side scatter. Step 2, 
human haematopoietic cells were gated based on expression of human 
CD45. Step 3, human T cells were gated based on expression of CD3. 
Step 4, T cell subsets were gated based on the expression of human CD8 
and CD4. Step 5, expression of activation markers (CD25 and HLA-DR) 
were analysed on the surface of CD4+ T cells (Supplementary Fig. 2c).
NHP sample collection and processing
EDTA-anticoagulated blood samples were collected regularly and 
used for a complete blood count, routine chemical analysis and 
immunostaining. Plasma was separated by centrifugation within 1 h 
of phlebotomy. At the end of the studies, tissue samples were col-
lected, including lymph nodes (21 rhesus macaques), spleen (10 rhesus 
macaques) and bone marrow (11 rhesus macaques). After 2 washes in 
RPMI and removal of connective and fat tissues, lymph nodes were 
ground using a 70-μm cell strainer. PBMCs and bone-marrow mono-
nuclear cells were prepared by density-gradient centrifugation. CD4+ 
T cells were negatively selected from fresh or frozen cell suspensions 
using magnetically labelled microbeads and subsequent column puri-
fication according to the manufacturer’s protocol (Miltenyi Biotec).
AZD5582 pharmacokinetics in NHPs
Three healthy male rhesus macaques of Indian origin (aged 6–7 years, 
10.5–13.0 kg) were used for the study. Fasted rhesus macaque received 
0.1 mg kg−1 of AZD5582 in 10% captisol and ≤5% DMSO (dose volume 
0.25 ml kg−1 at 0.40 mg ml−1), filtered during administration (0.22-μm 
PES in-line filter, Millex), via a 30-min saphenous vein infusion (infu-
sion pump, Harvard Apparatus). Blood from femoral venipuncture 
or saphenous catheters was collected to obtain samples for plasma 
pharmacokinetics (K2 EDTA microtainers spun at 13,000 rpm for 5 min 
to obtain plasma), flow cytometry (Cytochex tubes (Streck)) and PBMC 
isolation (CPT blood collection tubes, BD Biosciences) processed 
according to the manufacturers’ instructions and a dry pellet of cells 
was snap-frozen on dry ice and stored at −80 °C at various times after 
administration. AZD5582 was extracted from macaque plasma samples 
with an isotopically labelled internal standard (rilpivirine-d6) using 
protein precipitation. The compound was then eluted from a Waters 
Atlantis T3 (50 mm × 2.1 mm, 3 μm particle size) analytical column under 
reverse-phase conditions and detected on an AB Sciex API-5000 triple 
quadrupole mass spectrometer under TurboIonspray mode. Standards 
were prepared in singlet and quality controls in duplicate, and a calibra-
tion curve was generated using a weighted 1/(x2) linear regression of 
the concentration (x) versus the analyte:internal standard peak area 
ratio (y). Concentrations of quality controls and study samples were 
calculated from this calibration curve using Sciex Analyst Software 
(v.1.6.2). The acceptance criterion of the assay was ±25% of the nominal 
concentration for standards and quality controls, and the quantifiable 
range was 2–2,000 ng ml−1.
Ex vivo analysis of AZD5582 activity in NHP cells
Splenocytes from rhesus macaques were initially processed as above 
and frozen in FBS and 10% DMSO. Cryopreserved splenocytes were 
thawed and exposed to a range of concentrations of AZD5582 for either 
48 h continuously or for 1 h after which the drug was removed by wash-
ing and cells were further cultured for 47 h. In preparation for western 
blot analysis, cells were lysed on ice with intermittent vortex mixing 
using NP40 Cell Lysis Buffer (Invitrogen, FNN0021) supplemented 
with appropriately diluted 10× Protease Inhibitor Cocktail (Sigma, 
P-2714), 1 mM PMSF (Sigma, 93482) and 1 mM DTT (Sigma, 43816) to 
create a final concentration of 1 mM each in the complete lysis buffer. 
The lysed cells were then centrifuged at 13,000 rpm for 10 min at 4 °C 
and then supernatants (soluble fraction lysates) were removed and 
stored at −80 °C or used immediately for protein concentration and 
western blot analysis.
Flow cytometry assay for p100 protein
Whole blood collected in Cyto-Chex blood collection tubes (Myriad 
RBM) was added to ACK lysis buffer to remove red-blood cells, washed 
with PBS and resuspended in a staining cocktail that included anti-CD3 
BV421 (clone SP34-2, BD Biosciences), anti-CD16 BV605 (clone SG8, BD 
Biosciences), anti-CD4 BV711 (clone L200, BD Biosciences), anti-CD14 
BV786 (clone M5E2, BD Biosciences), anti-CD123 PerCP-Cy5.5 (clone 
7G3, BD Biosciences), anti-CD20 PE-CF594 (clone 2H7, BD Biosciences), 
anti-CD8 PE-Cy7 (clone SK1, BD Biosciences), anti-CD11c Alexa700 
(clone 3.9, eBioscience) and anti-HLA-DR APC-Cy7 (clone L243, BD 
Biosciences). After surface-staining, cells were washed twice with PBS, 
permeabilized using the Cytofix/Cytoperm kit (BD Biosciences, kit 
used as directed) and stained intracellularly with anti-p100 antibody 
(clone EPR18756; Abcam). Cells were washed twice and stained with a 
secondary chicken anti-rabbit Alexa Fluor 488 antibody (Invitrogen). 
Samples were acquired using a four-laser Fortessa flow cytometer (BD 
Biosciences) and analysed with FlowJo software (version 9.7.6, TreeStar).
SIV env sequencing and analysis
To generate env cDNA, reverse transcription of viral RNA was per-
formed using SuperScript III reverse transcriptase according to the 
manufacturer’s directions (Invitrogen) and the gene-specific primer 
SIVEnvR1 5′-TGTAATAAATCCCTTCCAGTCCCCCC-3′). Single-genome 
amplification of SIV env was performed by serially diluting this cDNA 
in independent PCR reactions to identify a dilution in which amplifica-
tion occurred in <30% of the total number of reactions. PCR amplifica-
tion was performed with 1× PCR buffer, 2 mM MgSO4, 0.2 mM of each 
deoxynucleoside triphosphate, 0.2 μM of each primer and 0.025 U μl−1 
Platinum Taq High Fidelity polymerase (Invitrogen) in a 20-μl reac-
tion. First-round PCR was performed with primer SIVEnvF1 5′-CCTC-
CCCCTCCAGGACTAGC-3′ and antisense primer SIVEnvR1 under the 
following conditions: 1 cycle of 94 °C for 2 min, 35 cycles at 94 °C for 
15 s, 55 °C for 30 s and 68 °C for 5 min, followed by a final extension 
of 68 °C for 10 min. Next, 1 μl from the first-round PCR product was 
added to a second-round PCR reaction that included the sense primer 
SIVEnvF2 5′-TATAATAGACATGGAGACACCCTTGAGGGAGC-3′ and anti-
sense primer SIVEnvR2 5′-ATGAGACATRTCTATTGCCAATTTGTA-3′ 
performed under the same conditions used for first-round PCR, but 
with a total of 45 cycles. Correctly sized amplicons were identified 
by agarose gel electrophoresis and directly sequenced with second-
round PCR primers and nine SIV-specific primers using BigDye Termi-
nator technology (Applied Biosystems). To confirm PCR amplification 
from a single template, chromatograms were manually examined for 
multiple peaks, indicative of the presence of amplicons that resulted 
from PCR-generated recombination events, Taq polymerase errors or 
multiple variant templates. Alignment and phylogenetic trees were 
implemented in Geneious Prime 2019 (Biomatters) using the Muscle 
algorithm and the neighbour-joining method with the Tamura–Nei 
genetic distance model, respectively.
Cell-associated SIV RNA and DNA quantification in NHPs
Cell-associated SIV RNA and DNA were measured simultaneously in rest-
ing CD4+ T cells isolated from peripheral blood, spleen, bone marrow 
and lymph nodes (52,279–500,000 cells) or in total CD4+ T cells iso-
lated from peripheral blood or lymph nodes (100,000–500,000 cells), 
lysed in RLT+ Buffer (Qiagen), and stored at −80 °C. Nucleic acids were 
extracted using the AllPrep DNA/RNA mini kit (Qiagen) according to 
the manufacturer’s recommendations with an on-column DNase diges-
tion step. Cell-associated DNA quantification of SIVmac239 gag DNA was 
performed on the extracted cell-associated DNA by qPCR using a 5′ 
nuclease (TaqMan) assay with SIV gag primers and normalized to the 
rhesus macaque albumin gene, as previously described47. For cell-
associated RNA quantification, RNA was reverse-transcribed using 
the High Capacity cDNA Reverse Transcription kit (ThermoScientific) 
and random hexamers. SIV gag and the rhesus macaque CD4 gene were 
quantified by qPCR of the resultant cDNA using Taqman Universal 
Mastermix II (ThermoScientific). The CD4 primer and probe sequences 
were Rh-CD4-F 5′-ACATCGTGGTGCTAGCTTTCCAGA-3′, Rh-CD4-R 
5′-AAGTGTAAAGGCGAGTGGGAAGGA-3′ and Rh-CD4-probe 5′-AGGC-
CTCCAGCACAGTCTATAAGAAAGAGG-3′. The means of two replicate 
wells were used in all analyses. Samples with undetectable SIV DNA or 
RNA were assigned a level of 1 copy per million cells or million CD4 RNA 
copies, respectively, for display purposes.
SIV quantitative viral outgrowth assay
Replication-competent SIV reservoirs were measured by the Viral Res-
ervoir Core Laboratory of the Emory Center for AIDS Research. Latently 
infected cells were quantified using a limiting dilution culture assay in 
which CD4+ T cells—enriched from lymph node or spleen cells using 
magnetic beads and column purification (Miltenyi Biotec)—were co-
cultured with CEMx174 cells in fivefold serial dilutions ranging from 
5 × 106 cells per well to 4 × 105 cells per well. The cells were cultured 
in RPMI containing 10% FBS and 100 U ml−1 IL-2 (Sigma). The ratio of 
target cells added was 4:1 for the two highest dilutions. A constant num-
ber of 1 × 106 CEMx174 cells was added to all other wells. The cultures 
were split every 7 days, and fresh medium was added. After 21 days, 
the growth of virus was detected by RT–qPCR. SIV RNA was isolated 
from 400 μl of culture supernatant using the Zymo viral RNA isolation 
kit (Zymo Research). DNase treatment was performed using a RQ1 
RNase-free DNase kit (Promega). A one-step RT–qPCR targeting SIV 
gag was performed using an Applied Biosystems 7500 Real Time PCR 
System (Applied Biosystems) and the Taqman Fast Virus 1-step Master 
Mix (Thermo Scientific) for qRT–PCR with the following primers and 
probe: SIVgagFwd 5′-GCAGAGGAGGAAATTACCCAGTAC-3′, SIVgagRev 
5′-CAATTTTACCCAGGCATTTAATGTT-3′ and SIVgag probe 5′-6FAM-
TGTCCACCTGCCATTAAGCCCGA-3IBFQ-3′. The frequencies of infected 
cells were determined by the maximum-likelihood method48 and were 
expressed as infectious units per million CD4+ T cells.
RNA-sequencing analysis of NHP cells
RNA-sequencing (RNA-seq) analysis was conducted at the Yerkes Non-
human Primate Genomics Core Laboratory (http://www.yerkes.emory.
edu/nhp_genomics_core/). RNA was purified from 50,000 peripheral-
blood- or lymph-node-derived CD4+ T cells, which were purified by flow 
cytometry and lysed in 350 μl of RLT buffer at −80 °C, using Qiagen 
Micro RNEasy columns, and RNA quality was assessed using an Agilent 
Bioanalyzer. Then, 2 ng of total RNA was used as input for mRNA ampli-
fication using 5′ template switch PCR with the Clontech SMART-seq v4 
Ultra Low Input RNA kit according to the manufacturer’s instructions. 
Amplified mRNA was fragmented and appended with dual-indexed bar 
codes using Illumina NexteraXT DNA library preparation kits. Libraries 
were validated by capillary electrophoresis on an Agilent 4200 TapeSta-
tion, pooled and sequenced on an Illumina HiSeq 3000 using 100-bp 
single reads at an average depth of 25 million reads.
RNA-seq statistical analyses
RNA-seq data were mapped to the MacaM (v.7.8) assembly of the Indian 
rhesus macaque genome49 (available at https://www.unmc.edu/rhe-
susgenechip/index.htm) and alignment was performed with STAR 
(v.2.5.2) using the annotation as a splice junction reference. Transcripts 
were annotated using the MacaM (v.7.8.2) annotation. Transcript abun-
dance was estimated within STAR using the htseq-count algorithm 
and differential-expression analyses were performed using DESeq2. 
For significance testing using DESeq2, all of the samples from three- 
and ten-dose rhesus macaques were grouped together, separately 
for peripheral blood and lymph nodes, and compared with their pre-
treatment samples. Genes determined to be differentially expressed by 
DESeq2 (adjusted P < 0.05 and fold change > ±1.5) were tested for enrich-
ment of molecular pathways using the DAVID database50 (https://david.
ncifcrf.gov/) and by using GSEA with the desktop module (https://www.
broadinstitute.org/gsea/). Gene sets for GSEA analysis were selected 
from the MSigDB database (http://software.broadinstitute.org/gsea/
msigdb/index.jsp) and from the previously described ‘blood transcrip-
tome modules’51. Heat maps, DAVID enrichment bar charts and GSEA 
enrichment plots were generated with the R (v.3.5.0) package ggplot2. 
Principal component analysis was performed using Partek Genomics 
Suite software (v.6.6) using a covariance matrix.
Immunophenotyping of NHPs by flow cytometry
Multicolour flow cytometry analysis was performed on whole blood 
and lymph-node mononuclear cells using predetermined optimal con-
centrations of the following fluorescently conjugated monoclonal anti-
bodies: CD3 APC-Cy7 (clone SP34-2), Ki-67 AF700 (clone B56), HLA-DR 
PerCP-Cy5.5 (clone G46-6), CCR5 APC (clone 3A9), CCR7 FITC (clone 
A20), CD45RA PE-Cy7 (clone 5H9) and CD62L PE (clone SK11) (all from 
BD Biosciences); CD8 BV711 (clone RPA-T8), CD4 BV650 (clone OKT4), 
CD95 BV605 (clone DX2) and PD-1 BV421 (clone EH12.2H7) (all from 
Biolegend) and CD28 PE-Cy5.5 (clone CD28.2) (from Beckman Coulter). 
Flow cytometry acquisition and analysis of samples was performed 
on at least 100,000 events on an LSRII flow cytometer driven by the 
FACSDiva software package (BD Biosciences). Analyses of the acquired 
data were performed using FlowJo software (Tree Star, v.10.0.4).
ELISPOT for SIV-specific IFNγ production in NHPs
IFNγ production was evaluated after the stimulation of PBMCs with 
SIVmac239 Gag and SIVmac239 Env peptide pools. The following reagents 
were obtained through the NIH AIDS Reagent Program, Division of 
AIDS, NIAID, NIH: SIVmac239 Env Peptide Pool and the SIVmac239 Gag Pep-
tide Pool. To analyse IFNγ expression, we used the Monkey Elispot kit 
from MABTECH. The manufacturer’s instructions were followed as 
provided with the exception that concanavalin A (final concentration 
of 2.5 μg ml−1) was used as the positive control agent. ELISPOT plates 
were blocked for 30 min with 100 μl of RPMI 1640 supplemented with 
10% FBS. PBMCs (4 × 105 per well) were incubated with 1 μg ml−1 of DMSO, 
SIVmac239 Gag Peptide Pool or SIVmac239 Env Peptide Pool for 18 h before 
running the assay. For each plate, concavalin A was used for the positive 
control wells. Samples were run in duplicate.
Intracellular cytokine staining
PBMCs from five ART-suppressed SIV-infected rhesus macaques were 
thawed. Pre-treatment with AZD5582 was performed for 1 h at 100 nm. 
After two washes, phorbol 12-myristate 13-acetate (PMA) and ionomycin 
were added for 1 h at 500 ng ml−1 and 10 μg ml−1, respectively. DMSO 
treatment controls were prepared in parallel. After 1 h, brefeldin-A 
and Golgi stop solution were added following the manufacturer’s rec-
ommendations (BD GolgiStop Protein Transport Inhibitor, BD Bio-
sciences). Cells were incubated at 37 °C, 5% CO2 in R10 for 6–8 h before 
staining with the following antibodies: CD3 APC-Cy7 (clone SP34-2), 
CD8 BV711 (clone RPA-T8), CD4 BV650 (clone OKT4) (all from Bioleg-
end), and IFNγ PE (clone B7), TNF AF700 (clone Mab11) and IL-2 BV605 
(clone MQ1-17H12) (all from BD Biosciences). Flow cytometry acquisi-
tion and analysis of samples was performed on at least 100,000 events 
using an LSRII flow cytometer driven by the FACSDiva software package 
(BD Biosciences). Analyses of the acquired data were performed using 
FlowJo (TreeStar, v.10.0.4) and simplified presentation of incredibly 
complex evaluations (SPICE, v.6.0)52 software.
Proliferation assay
PBMCs from five ART-suppressed SIV-infected rhesus macaques were 
thawed and labelled with CellTrace Violet Proliferation Kit accord-
ing to the manufacturer instructions (Molecular Probes). Cells were 
plated in R10 in 96-well round-bottom plates at 4 million cells per ml. 
Pre-treatment with AZD5582 was performed for 1 h at 100 nM. After 
two washes, PMA and ionomycin were added for 1 h at 500 ng ml−1 and 
10 μg ml−1, respectively. DMSO treatment controls were prepared in 
parallel. Cells were incubated at 37 °C, 5% CO2 in R10 supplemented 
with 20 IU ml−1 IL-2. After 5 days, cells were stained with CD3 APC-Cy7 
(clone SP34-2), CD8 BV711 (clone RPA-T8), CD4 BV650 (clone OKT4) 
(all from Biolegend) and analysed by flow cytometry on an LSRII instru-
ment. Data were analysed using FlowJo software (TreeStar, v.10.0.4).
Statistical analysis
Statistical analyses were performed using GraphPad Prism Software (v.6 
or v.7). P ≤ 0.05 was considered statistically significant. At least three sam-
ples were used for each group, the minimum to achieve statistical signif-
icance. No statistical methods were used to predetermine sample size. 
Investigators were not blinded to group allocations or when assessing 
 outcomes. In some instances, cells were pooled from individual 
humanized mice for each tissue and experimental group for the iso-
lation of resting CD4+ T cells (Fig. 2d and Extended Data Fig. 2). To test 
the statistical significance of the differences that we observed in PCR 
data in BLT mouse brains in Fig. 2e and grouped tissue PCR data in 
Fig. 2d, unpaired two-sided Student’s t-tests were used. To test the 
statistical significance of the differences that we observed in PCR data 
in PBMCs and female reproductive tract in Fig. 2e, T cell activation mark-
ers in Supplementary Table 5 and plasma cytokines and chemokines in 
Supplementary Table 6, we used unpaired two-sided Mann–Whitney 
U-tests. To assess the statistical significance of the differences observed 
over time in serum enzymes in Supplementary Table 4, we used paired 
nonparametric Wilcoxon matched-pairs signed-rank tests. To test the 
statistical significance of the differences in activation marker levels 
expressed on T cells from rhesus macaques in Fig. 4d, e, as well as the 
ultrasensitive plasma viral load results in Extended Data Fig. 8b and the 
ex vivo proliferation assay in Extended Data Fig. 10g, we used Wilcoxon 
matched-pairs signed-rank tests. To assess the statistical significance 
of the differences observed between SIV DNA and SIV RNA levels in rest-
ing or total CD4+ T cells from rhesus macaques in Fig. 3e and Extended 
Data Fig. 6b, respectively, as well as for the quantitative viral outgrowth 
results in Extended Data Fig. 6c, we used unpaired two-sided Mann–
Whitney U-tests. Unpaired two-sided Mann–Whitney U-tests were also 
used to compare rhesus macaques with stable compared with increased 
viraemia in Extended Data Fig. 8c.
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Further information on research design is available in the Nature 
Research Reporting Summary linked to this paper.
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Extended Data Fig. 1 | Short-duration exposure to AZD5582 activates the 
ncNF-κB pathway. a–d, Isolated total human CD4+ T cells treated with 100 nM 
AZD5582 and then either not washed (a) or washed three times with PBS 8 h (b), 
4 h (c) or 1 h (d) after treatment. Whole-cell lysates were then analysed by 
immunoblot for components of the ncNF-κB pathway. e, Densitometry analysis 
of the ratio of p52 to p100 from the pulse-wash assay immunoblots. Points 
represent values for the densitometric ratio from one western blot, 
representative of several independent experiments. a–e, Entire set 
representative of 1 experiment with 5 replicates of the 1-h wash condition 
conducted. f, Fold induction of ncNF-κB target gene expression in isolated 
CD4+ T cells from an uninfected donor treated with the indicated 
concentrations of AZD5582 and either washed after 1 h or not washed, and 
subsequently cultured for 24 h as measured by RT–qPCR. Points represent two 
technical replicates and lines represent the mean. The data presented are 
representative of three independent experiments. g, DMSO-normalized 
induction of luciferase activity from the Jurkat reporter model after exposure 
to AZD5582 (10, 100 or 1,000 nM) for 30 min (blue), 1 h (red), 2 h (green) or 
continued exposure (purple). Points represent three replicates in one assay 
run, representative of two independent experiments. Lines represent the mean 
of the three replicates. For gel source data, see Supplementary Fig. 1.
Extended Data Fig. 2 | AZD5582 induces HIV RNA expression in resting CD4+ 
T cells from tissues of HIV-infected, ART-suppressed BLT mice. HIV RNA 
levels in resting CD4+ T cells isolated from the bone marrow, lymph nodes, liver, 
lung and spleen of control (Cntrl, blue circles) or AZD5582-treated (AZD, red 
circles) mice (cells pooled from n = 6 mice per group for each tissue) were 
analysed in triplicate. Statistical significance was determined with a two-sided 
Student’s t-test. The mean fold increase in viral RNA levels in resting CD4+ 
T cells from tissues in the experiment shown in Fig. 2 was 12.1 (±3.7), whereas in 
this figure it was 8.4 (±6.0). These values were not statistically different 
(P = 0.4286, two-sided Mann–Whitney U-test). Data are mean ± s.e.m.
Extended Data Fig. 3 | AZD5582 ex vivo target engagement. a, Western blot 
analysis of p100, p52 and cIAP1 protein levels in cells isolated from the bone 
marrow, lymph node and spleen of BLT mice before and 20 h after ex vivo 
treatment with AZD5582. Loading control, β-actin. Representative of two 
experiments. b, cIAP expression in resting CD4+ T cells isolated from the 
thymus, spleen, lymph nodes, liver, lung and bone marrow. Loading control, 
β-actin. Representative of two experiments. c, cIAP expression in the thymic 
organoid of HIV-infected ART-suppressed BLT mice 48 h after the 
administration of vehicle control or AZD5582 (three control and one AZD5582-
treated analysed). Positive cells, brown. Imaged at 4× and 40× magnifications; 
scale bars, 100 μm (4×) and 50 μm (40×). Boxes in the 4× images indicate 
regions corresponding to images at 40× magnification. For gel source data, see 
Supplementary Fig. 1.
Extended Data Fig. 4 | Pharmacokinetic and pharmacodynamic assessment 
of AZD5582 in rhesus macaques. a, AZD5582 (0.1 mg kg−1) was administered  
to healthy rhesus macaques (n = 3) by intravenous infusion. Plasma 
concentrations of AZD5582 (left y axis) are shown for the indicated time points. 
Flow cytometry was used to measure intracellular p100 levels, shown as the 
geometric mean fluorescence intensity (gMFI) in CD4+ T cells and plotted as 
the percentage of baseline of p100 gMFI (right y axis). b, Plasma concentrations 
of AZD5582 after one (dark red), three (red), six (pink) or ten (orange) doses in 
six SIV-infected ART-treated rhesus macaques (RM) and after one dose in three 
uninfected control rhesus macaques (grey). Individual values are shown as 
symbols. c, Western blot analyses of inactive p100 and active p52 forms of NF-
κB2 in lymph-node mononuclear cells collected 48 h after the third or tenth 
dose of AZD5582 in SIV-infected ART-suppressed rhesus macaques (red; n = 3 
for both the 3-dose and 10-dose groups) or at equivalent time points for 
placebo controls (blue; n = 2 for both the 3-dose and 10-dose groups). 
Immunoblots are shown in the top panels and densitometry analyses of the 
p52:p100 ratios are shown in the bottom panels. The line represents the 
median. d, Cryopreserved control rhesus macaque splenocytes were treated 
with the indicated concentrations of AZD5582 for 48 h, then p100/p52 levels 
were analysed by western blotting to measure engagement of the ncNF-κB 
pathway. e, DMSO-normalized densitometric p52:p100 ratio versus the 
AZD5582 concentration. For d, e, the experiments were performed in 
duplicate. f, Cryopreserved rhesus macaque splenocytes were exposed to 
DMSO alone (Untx), 100 nM AZD5582 washed off after 1 h and cultured for 47 h 
(Pulsed) or continuous 100 nM AZD5582 for 48 h (Cont.), after which the cells 
were studied by western blot for p100 and p52 levels. g, Densitometric 
p52:p100 ratio. For f, g, data represent a single experiment. For gel source data, 
see Supplementary Fig. 1.
Extended Data Fig. 5 | Phylogenetic trees based on full env sequencing. 
Plasma virus was sequenced from four time points per macaque (n = 5): near 
peak viraemia (2 weeks after infection; red), immediately before ART (8 weeks 
after infection; orange) and two time points of on-ART viraemia during 
AZD5582 treatment (green and blue). All sequences per macaque were 
phylogenetically analysed and the resulting phylogenetic trees are shown for 
each macaque. The horizontal bar indicates the genetic distance. nt, 
nucleotide.
Extended Data Fig. 6 | SIV DNA levels in total CD4+ T cells and replication-
competent reservoir size in ART-suppressed SIV-infected rhesus macaques. 
a, Longitudinal assessment of cell-associated SIV DNA levels in total CD4+ 
T cells isolated from peripheral blood and lymph nodes of AZD5582-treated 
(n = 12, red) and control (n = 4, blue) ART-suppressed SIV-infected rhesus 
macaques. Grey shading represents the period of ART administration.  
b, Comparison of cell-associated SIV DNA levels in total CD4+ T cells isolated 
from the lymph nodes and peripheral blood of AZD5582-treated and control 
ART-suppressed SIV-infected rhesus macaques. Total CD4+ T cells were 
analysed from AZD5582-treated rhesus macaques 48 h after receiving 3 doses 
(lymph nodes and peripheral blood, n = 3) or 10 doses (lymph nodes and 
peripheral blood, n = 9) of AZD5582. Total CD4+ T cells were analysed from 
placebo-control rhesus macaques (lymph nodes and peripheral blood, n = 4)  
at equivalent time points. Open symbols indicate AZD5582-treated rhesus 
macaques with on-ART viraemia above 60 copies per ml of plasma. Statistical 
significance was determined using a two-sided Mann–Whitney U-test.  
c, Quantitative viral outgrowth assays were performed for AZD5582-treated 
rhesus macaques 48 h after receiving 3 doses (lymph nodes, n = 2; spleen, n = 3) 
or 10 doses (lymph nodes, n = 3; spleen, n = 2) of AZD5582. Quantitative viral 
outgrowth assays were performed from control rhesus macaques (lymph 
nodes and spleen, n = 4) at equivalent time points. Open symbols indicate 
AZD5582-treated rhesus macaques with on-ART viraemia. Statistical 
significance was determined with a two-sided Mann–Whitney U-test. 
Horizontal lines represent the median (b, c).
Extended Data Fig. 7 | AZD5582-induced gene pathways and genes in SIV-
infected ART-suppressed rhesus macaques. a, DAVID analysis showing 
pathways significantly enriched in genes differentially expressed after 
AZD5582 treatment relative to baseline in CD4+ T cells isolated from lymph 
nodes (black bars) and peripheral blood (grey bars). n = 6 for both lymph nodes 
and peripheral blood; for each, n = 3 for 3 doses of AZD5582 and n = 3 for 10 
doses of AZD5582. b, Leading edge genes from the ‘hallmark TNF signalling via 
NF-κB’ pathway from MSigDB. Genes were identified in the leading edge of 
CD4+ T cell samples from the lymph nodes before and after treatment with 
AZD5582 (shown in Fig. 4b). The contrast depicted is the fold change of each 
gene for each rhesus macaque’s post-treatment sample relative to the pre-
treatment values for CD4+ T cells from the lymph nodes (top) and the 
peripheral blood (bottom). n = 6 for both lymph nodes and peripheral blood; 
for each, n = 3 for 3 doses of AZD5582 and n = 3 for 10 doses of AZD5582. c, Heat 
map of cNF-κB (top) and ncNF-κB (bottom) pathway gene expression in rhesus 
macaques with (left, n = 5) or without (right, n = 6) on-ART viraemia of 
>60 copies per ml plasma. One rhesus macaque without on-ART viraemia was 
excluded from this analysis because of technical issues (higher than expected 
unmapped and multi-mapped reads, and lower than expected unique 
identified reads compared to the means). Colour scale, log2-transformed fold 
changes of post-treatment compared with pre-treatment values.
Extended Data Fig. 8 | Relationship between virological status before 
intervention and virological response to AZD5582 treatment in SIV-
infected ART-suppressed rhesus macaques. a, Individual representations of 
plasma SIV RNA levels measured by ultrasensitive assay (limit of detection 
3 copies per ml of plasma) before and during AZD5582 treatment in SIV-
infected ART-suppressed rhesus macaques (n = 12). ‘Baseline’ shows two or 
three plasma viral loads before AZD5582 treatment and ‘AZD5582’ shows three 
or four plasma viral loads during AZD5582 treatment. Open symbols indicate 
the five AZD5582-treated rhesus macaques with on-ART viraemia of >60 copies 
of SIV RNA per ml of plasma using the standard viral load assay (confirmed with 
ultrasensitive assay). The orange box highlights an additional 3 rhesus 
macaques who did not experience on-ART viraemia of >60 copies per ml of 
plasma but had ≥2 SIV RNA measurements above baseline values using the 
ultrasensitive quantification method. b, Comparison of the medians of plasma 
SIV RNA levels at baseline and during AZD5582 treatment measured by 
ultrasensitive assay for ART-suppressed SIV-infected rhesus macaques (n = 12). 
Statistical significance was determined with a Wilcoxon matched-pairs signed-
rank test. c, Comparison of the levels of plasma SIV RNA at peak, plasma SIV 
RNA before ART initiation, SIV DNA in peripheral-blood CD4+ T cells before 
AZD5582 treatment (pre-LRA), SIV DNA in lymph-node CD4+ T cells pre-LRA, 
SIV RNA in peripheral blood CD4+ T cells pre-LRA and SIV RNA in lymph-node 
CD4+ T cells pre-LRA in rhesus macaques with increased plasma viral loads 
(PVL) by standard and/or ultrasensitive assay during AZD5582 treatment 
(increased plasma viral loads, n = 8) compared with rhesus macaques that did 
not demonstrate increased viral loads (stable plasma viral loads, n = 4). 
Statistical significance was determined using a two-sided Mann–Whitney  
U-test. Horizontal lines represent the median (a, c).
Extended Data Fig. 9 | AZD5582 can be safely administered in SIV-infected 
ART-suppressed rhesus macaques. a–c, Longitudinal assessment of serum 
chemistries (a), complete blood counts (b) and weight (c) of SIV-infected ART-
treated rhesus macaques treated with AZD5582 (red, n = 12) compared with 
controls (blue, n = 9). Grey shading represents the period of ART 
administration. AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; BUN, blood urea nitrogen; GGT, γ-glutamyltransferase; 
HGB, haemoglobin; WBC, white blood cell.
Extended Data Fig. 10 | Immunological effect of AZD5582 on SIV-infected 
ART-suppressed rhesus macaques. a, b, Longitudinal assessment of the count 
(a) and the frequency and viability (b) of CD4+ T cells in SIV-infected ART-
treated rhesus macaques during the period of AZD5582 treatment (n = 12). 
Lines represent median values. c, d, CD4+ T cell naive and memory subset 
frequencies (c) and their expression of Ki-67 (d) in SIV-infected ART-treated 
rhesus macaques during the period of AZD5582 treatment (n = 12). Lines 
represent median values. e, SIV gag-specific (left) and SIV env-specific (right)
CD8+IFNγ+ T cell responses in SIV-infected, ART-suppressed, AZD5582-treated 
(red, n = 6) and control (blue, n = 4) rhesus macaques. SFU, spot-forming units. 
f, Pie charts depicting the ability of memory CD8+ T cells isolated from SIV-
infected ART-suppressed control rhesus macaques (n = 5) to produce IFNγ, IL-2 
and/or TNF in response to stimulation with PMA and ionomycin in the absence 
(left) or presence (right) of AZD5582 pre-treatment. g, Memory CD8+ T cell 
proliferative response to stimulation with PMA and ionomycin with or without 
AZD5582 pre-treatment. Top, representative flow cytometry dot plots gated 
on memory CD8+ T cells. Bottom, comparison between divided cells 5 days 
after stimulation in each group (n = 5 for each). Statistical significance was 
determined with a Wilcoxon matched-pairs signed-rank test. Horizontal lines 
represent the median. h, Longitudinal assessment of plasma levels of IP-10, 
MIP-1β, MCP-1, IL-6 and IL-10 by multiplex assay in SIV-infected ART-suppressed 
rhesus macaques treated with AZD5582 (red, n = 6) or control rhesus macaques 
(blue, n = 4). An additional four analytes (IFNγ, IL-8, IL-1β and IL-2) were 
undetectable in all macaques. a–e, h, Grey shading represents the period of 
ART administration. Dashed lines represent AZD5582 or placebo infusions. 
LLOD, lower limit of detection.
